Tier 2 — strong

Evaluation of the Efficacy and Safety of CollaSel PRO Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Devrim Demir-Dora, Serpil Tuna, Emel Dogan Kurtoglu, Savas Gursoy, Nilufer Balci, Selim Tezman, Aydin Erenmemisoglu
Journal of Clinical Medicine 2025 14(11):3655

Bibliography

PubMed
PMID 40507417
PubMed Central
PMC12156922
DOI
10.3390/jcm14113655
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
The study was funded by Sel Sanayi Ürünleri Ticaret ve Pazarlama A.Ş., the supplier of the CollaSel PRO test product.
Competing interests
The paper discloses an author relationship with Sel Sanayi, the test-product supplier, and another author affiliation with the contract research organization involved in the study; other authors reported no conflicts as detailed in the article.

Study snapshot

DesignDouble-blind randomized parallel placebo-controlled clinical trial in two university physical-medicine centers
ModelMean age 52.4 years; symptomatic osteoarthritis
Sample160 adults with knee, hip or ankle OA (80 active, 80 placebo; 111 female, 49 male)
Intervention10 g/day proprietary type I/III hydrolyzed CollaSel PRO vs 10 g/day maltodextrin placebo
Duration8 weeks; visits at weeks 1, 4 and 8
EndpointsWOMAC knee/hip pain and function; AOFAS ankle-hindfoot scores; Tolerability

What the study showed, in plain terms

A 160-person trial of a defined 10-g/day type I/III hydrolyzed collagen product reported lower knee/hip WOMAC scores and better ankle AOFAS outcomes versus placebo by weeks 4 and 8.

Key findings

Significant between-group improvement in WOMAC and AOFAS by weeks 4 and 8 (reported p<0.001); short-term tolerability was favorable.

What this study can and cannot tell us

The trial tested proprietary CollaSel PRO rather than the DoNotAge formulation and included industry-linked authors associated with product supply. The eight-week outcomes were symptomatic and did not demonstrate structural cartilage regeneration or joint-replacement prevention. Multiple joint sites, repeated time points and site-specific analyses create multiplicity concerns, so interpretation should focus on prespecified between-group outcomes rather than within-group changes alone.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology